Subcutaneous Ocrevus, by Genentech, Shows Almost Total Control of Clinical Relapses and Brain Lesions Over a Year in Progressive and Relapsing MS Cases.
Eloxx Pharmaceuticals, Inc. announced recent developments in their programs for ELX-02 and ZKN-013, highlighting the Orphan Drug Designation awarded to ELX-02.
In the TOPAZ-1 Phase III trial, the combination of Imfinzi and chemotherapy increased the three-year overall survival rate by twofold in patients with advanced biliary tract cancer.
Neurona Therapeutics Reports Encouraging Results from Its NRTX-1001 Cell Therapy Study in Adults Suffering from Drug-resistant Focal Epilepsy at the 2024 AAN Annual Meeting.
Latest findings from Novartis on Fabhalta® (iptacopan) reveal a notable and statistically significant decrease in proteinuria by 38.3% compared to placebo in individuals suffering from IgA nephropathy (IgAN).
NiKang Therapeutics has administered the initial dose to a patient in its Phase 1/1b trial of NKT3447, an oral drug targeting CDK2 that decreases Cyclin E levels.